This study is currently not recruiting participants.

GOG-0238; A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

Investigating Radiation Therapy with Investigational Medication for Recurrent Endometrial Cancer

Not Recruiting
100 years or below
Female
Phase N/A

Brief description of study.

This randomized phase II trial studies radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with endometrial cancer that has come back.

Detailed description of study

The purpose of this study is to assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Carcinoma of the Uterine Corpus
  • Age: 100 years or below
  • Gender: Female

This study investigates the effectiveness of radiation therapy combined with an investigational medication in treating patients with endometrial cancer that has returned. Endometrial cancer affects the lining of the uterus. The study aims to see if adding the investigational medication to radiation therapy improves outcomes compared to radiation therapy alone.

Participants in this study will undergo radiation therapy. Some will also receive an investigational medication called cisplatin, which is given to see if it can improve progression-free survival. Progression-free survival refers to the length of time during and after treatment that a patient lives with the disease without it getting worse.

  • Who can participate: The study is for patients with recurrent uterine carcinoma limited to the pelvis and vagina, with a confirmed diagnosis of endometrial cancer that has returned after initial treatment.
  • Study details: Participants will receive either radiation therapy alone or radiation therapy combined with an investigational medication called cisplatin. Cisplatin is used to see if it can improve treatment outcomes.
Updated on 19 Feb 2024. Study ID: 1105005612 (0805-37)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team